Bharat Biotech International Ltd has initiated clinical trials for the Tuberculosis vaccine Mtbvac on adults in India. Developed by the Spanish biopharmaceutical company Biofabri, Mtbvac is the first TB vaccine derived from a human source. The vaccine aims to be more effective and longer-lasting than the current BCG vaccine for newborns and to prevent TB in adults and adolescents, for whom there is currently no effective vaccine. The trials are a significant step, especially in a country like India where 28% of the world's TB cases occur.